International Journal of Pharmacy and Analytical Research (IJPAR)

IJPAR |Vol.14 | Issue 1 | Jan - Mar -2025

www.ijpar.com

ISSN: 2320-2831

DOI : https://doi.org/10.61096/ijpar.v14.iss1.2025.95-102

Review

A review on analytical methods for the estimation of carisoprodol in bulk and its formulations

M. Narendra*, Y. Mallika, V. Devaraju, Y. Lakshmi likhitha, Chennupati Suresh

Chennupati Indo-American School Of Pharmacy jonnalagadda, narasaraopet, Andhra Pradesh, India

*Author for Correspondence: M. Narendra
Email: shalemraju115@gmail.com

Published on: 17 Feb 2025

Published by:
DrSriram Publications

Abstract

This review focuses on the analytical methods for the estimation of carisoprodol in bulk and its pharmceutical preperations. Carisoprodol is a centrally acting skeletal muscle relaxant widely used to alleviate acute musculoskeletal pain. It is metabolized into meprobamate, which contributes to its therapeutic effects. I mentioned the drug profile and chemical structure of carisoprodol and introduction, mechanism of action, pharmacokinetics and some Analytical techniques are used to detect the quantitative and qualitative analysis such as UV-Spectroscopy, High-Performance Liquid Chromatography (HPLC), Thin Layer Chromatography (TLC),Gas chromatography (GC), Capillary electrophoresis (CE) and Fourier Transform Infrared Spectroscopy (FTIR) by each method I have mentioned some authors and they getting parameter values have been applied to determine Carisoprodol's precision, accuracy, linearity, and sensitivity.

Keywords: carisoprodol

INTRODUCTION

Carisoprodol is a carbamate derivative it is commonly prescribed for the treatment of musculoskeletal conditions such as sprains and strains. It exhibits muscle relaxant properties by interrupting neuronal communication in the spinal cord and brain [5,6]. Due to its rapid onset of action. And Carisoprodol has become a preferred choice for short-term relief of pain associated with muscular injuries. Its efficacy is enhanced by its active metabolite, meprobamate, which have sedative properties [7–9].

Drug profile

- Name: Carisoprodol
- Synonyms: Soma, Carisoma, Carisoprodol
- Molecular Formula: C12H24N2O4S
- Molecular Weight: 260.38 g/mol

Structure



Pharmacology

- **Class:** Muscle relaxant, Centrally acting skeletal muscle relaxant
- **Mechanism of Action**: Interferes with neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration of pain perception
- **Therapeutic Effects**: Relaxes muscles, relieves pain and discomfort
- Indications
- Approved Uses: Relief of acute, musculoskeletal discomfort
- **Off-Label Uses**: Fibromyalgia, restless leg syndrome, migraine prophylaxis

Mechanism of action

Carisoprodol is a centrally acting skeletal muscle relaxant . Action that involves both direct and indirect pathways. Its effects are mediated through the central nervous system (CNS) rather than acting directly on skeletal muscle tissue.

Primary Mechanism

Carisoprodol functions by interrupting neuronal communication within the reticular formation and spinal cord. This leads to sedation and a reduction in the transmission of pain signals, providing relief from muscle spasms and associated discomfort and It does not directly affect neuromuscular junctions or skeletal muscle fibers.

Role of the Active Metabolite (Meprobamate)

Carisoprodol is metabolized in the liver by the CYP2C19 enzyme into meprobamate, an active metabolite that contributes significantly to its pharmacological effects. Meprobamate acts on gamma-aminobutyric acid-A (GABA-A) receptors, enhancing the inhibitory effects of GABA, the primary inhibitory neurotransmitter in the CNS. This action produces sedative, anxiolytic, and muscle relaxant effects [7][11][12].

Sedative and Anxiolytic Effects

The sedative properties of carisoprodol is influenced on neuronal activity in the brain. By decreasing excitatory signals in the CNS and it helps relieve muscle tension and anxiety often associated with musculoskeletal conditions. where muscle relaxation and calming of the CNS are necessary [10][12].

Modulation of Pain Perception

Carisoprodol also alters the perception of pain by modulating sensory input to the CNS. The drug disrupts the feedback loop between the brain and spinal cord, which can reduce the sensation of pain and the reflexive of muscle spasms often triggered by injury. [7][11].

Lack of Direct Action on Skeletal Muscles

Carisoprodol does not shows a direct effect on skeletal muscle fibers or the neuromuscular junction. It acts purely central and targeting the CNS to achieve muscle relaxation indirectly. where muscle relaxation through central mechanisms is desired [5][13].

Potential for CNS Depression

Due to its action on the CNS, Carisoprodol can cause drowsiness, dizziness, and, in higher doses and CNS depression. The additive effects of its metabolite, meprobamate, can exacerbate these symptoms, particularly when combined with other CNS depressants such as alcohol or opioids. [11][16].

Implications

CYP2C19 polymorphisms can significantly influence the metabolism of Carisoprodol in Poor metabolizers may experience prolonged drug action and increased plasma levels or heightening the risk of sedation and adverse effects like Rapid metabolizers on the other hand may have higher concentrations of meprobamate it enhancing sedative effects [15][22].

Pharmacokinetic studies of carisoprodol

Carisoprodol is a centrally acting muscle relaxants. Its absorption, distribution, metabolism, and excretion make it suitable for the management of acute musculoskeletal conditions.

Absorption

Carisoprodol is rapidly absorbed from the gastrointestinal tract after oral administration, with peak plasma concentrations occurring within 1.5–2 hours. The drug demonstrates high bioavailability, which ensures fast therapeutic effects. Food does not significantly affect its absorption, making it convenient for patients [13][18][19].

Distribution

Once absorbed, Carisoprodol is widely distributed in the body, with a high volume of distribution (approximately 2.5–3.5 L/kg). The drug readily crosses the blood-brain barrier, enabling its central nervous system (CNS) effects. Protein binding is relatively low, allowing extensive tissue penetration. [14][20]

Metabolism:

Carisoprodol undergoes hepatic metabolism via the cytochrome P450 enzyme CYP2C19, producing its active metabolite, meprobamate. Meprobamate has anxiolytic and sedative properties, which enhance the muscle relaxant effects of Carisoprodol. However, CYP2C19 polymorphism can result in interindividual variability in metabolism, affecting drug
efficacy and safety. Poor metabolizers may experience higher plasma concentrations of Carisoprodol, increasing the risk of adverse effects.[15][24]

Excretion

Carisoprodol and its metabolites are primarily excreted through the kidneys. The half-life of Carisoprodol is approximately 8 hours, while meprobamate has a longer half-life (6–17
hours), leading to prolonged pharmacological effects. Accumulation of meprobamate in chronic use can result in sedation and dependency, requiring cautious administration
[17][23].

Special Populations

Elderly Patients: Slower metabolism may lead to higher drug levels, increasing the risk of sedation and falls ,Renal and Hepatic Impairment: Impaired kidney or liver function may reduce clearance, requiring dose adjustments [14][15].

Analytical methods for carisoprodol

Various analytical techniques have been detailed to quantify Carisoprodol in bulk and its pharmaceutical formulations. These includes:

UV-Spectroscopy

Development:

- Select a solvent that dissolves Carisoprodol well (e.g., methanol, ethanol, or water).
- Determine the wavelength of maximum absorbance (λmax) using a UV spectrum scan (e.g., 220–225 nm).
- Develop a calibration curve by preparing solutions of different concentrations (e.g., 1–10 µg/mL).[15][23]

UV Spectroscopy Calibration Curve

Concentration Range: Prepare standard solutions of Carisoprodol with varying concentrations.[15]
UV Absorption: Measure the absorbance of each solution at the wavelength where Carisoprodol shows maximum absorption (around 220 nm).[23]
Calibration Curve: Plot the absorbance values (y-axis) against the concentrations (x- axis). The slope of this curve can be used to determine the concentration of unknown samples based on their absorbance.[15]
Key Parameters by Sharma M, et al. (2012) - UV-Spectrophotometric Analysis of Carisoprodol in Formulations. Indian Journal of Pharmaceutical Sciences

1. Wavelength Selection (λmax): The maximum absorbance wavelength for Carisoprodol was found to be around 220 nm.
2. Calibration Curve: A linear relationship was established between absorbance and concentration (1–10 µg/mL).
3. Precision and Linearity: The method demonstrated good precision with repeatability across samples and showed a linear concentration-response($R^2 > 0.99$).
4. LOD/LOQ: Limits of detection and quantification were determined based on the signal-to-noise ratio.
5. Retention time: 4.9 min

Additional insights

If he is using derivative UV spectroscopy, it will improve the resolution of overlapping peaks or impurities that might interfere with Carisoprodol's λmax. If he includes comparative solvent studies, it can help identify which solvent provides the best sensitivity and linear response.





HPLC (High-Performance Liquid Chromatography)

Development:

Mobile Phase: Commonly a mixture of water and an organic solvent (like acetonitrile or methanol), depending on the nature of the sample and the column. [2]

Column: C18 reverse-phase columns are often used for Carisoprodol analysis.[2]

Detector: UV detector typically set around 220-254 nm, where Carisoprodol absorbs.[2]

Retention Time: The peak corresponding to Carisoprodol will have a specific retention time based on column and mobile phase composition.[2]

An HPLC chromatogram would show the retention time on the x-axis and the intensity (in mAU) on the y-axis. A peak at a specific retention time would indicate the presence of

Carisoprodol.[12][29]

Key Parameters by Patel J, et al. (2019) - Development of HPLC Method for Carisoprodol. International Journal of Pharmaceutical Sciences

Mobile Phase: A mixture of water and acetonitrile was used for efficient separation.

Retention Time: Carisoprodol showed a characteristic retention time (around 4.2–5.5 minutes) under optimized conditions.

Accuracy and Specificity: Accuracy was confirmed with recovery percentages in the range of 98–102%. Specificity was ensured by separating Carisoprodol from its impurities.

Validation Parameters:

Precision: Repeatability was demonstrated with standard deviation values below 2%.

Linearity: A linear correlation ($R^2 > 0.999$) was observed between the concentration and peak area.

LOD/LOQ: The limits of detection and quantification were successfully determined.

Additional insights

If he uses a diode-array detector (DAD) instead of a simple UV detector, it can help obtain spectral data for peak confirmation, thereby adding specificity.

Exploring alternative stationary phases, such as phenyl columns, can improve selectivity.

TLC (Thin-Layer Chromatography)
Development:
Stationary Phase: A silica gel plate is usually used.
Mobile Phase: A mixture of solvents such as chloroform, methanol, or ethyl acetate might be used depending on Carisoprodol's polarity.
Visualization: After development, Carisoprodol can be visualized by UV light (if it absorbs UV) or by spraying with a suitable reagent that reacts with Carisoprodol.
TLC Plate: You would observe a spot corresponding to Carisoprodol. The distance traveled by the spot can be compared to standards to confirm its identity.[21]
Key Parameters by Dixit K, et al. (2015) - TLC as a Qualitative Tool for Carisoprodol Analysis. International Journal of Pharmaceutical Research
Mobile Phase: A mixture of chloroform, methanol, and ethyl acetate was optimized for Carisoprodol
Stationary Phase: Silica gel plates were used for the separation.
Rf Value: The Rf value was recorded to help identify Carisoprodol. The spot's distance was compared with known standards.
Linearity: The relationship between spot area and concentration was linear **Precision**: The method demonstrated good repeatability when analyzed in duplicate. Additional insights
If he used high-performance TLC (HPTLC), it would provide better resolution and
enhanced quantitative capabilities.
If he introduced densitometric scanning, it would allow more accurate quantification by measuring the intensity of Carisoprodol spots.

GC (Gas Chromatography)
Development:
Sample Preparation: Since Carisoprodol is a relatively low-boiling compound, it is suitable for analysis by GC. It may require derivatization if it's not volatile enough or if it's not easily detectable by the detector.
Column: Typically, a non-polar column (such as a DB-1 or HP-5) would be used.
Detector: Flame Ionization Detector (FID) or Mass Spectrometer (MS) is common.[17]
Chromatogram: The GC chromatogram will have retention time on the x-axis and detector response (in arbitrary units) on the y-axis. Carisoprodol would show up as a peak at its characteristic retention time.[17][28]
Application: For purity testing or quantifying the concentration of Carisoprodol in a sample.
Key Parameters by Wang J, et al. (2009) - Gas Chromatographic Analysis of Carisoprodol. Journal of Analytical Toxicology
Column Type: Non-polar columns, such as DB-1 or HP-5, were used.
Detector: Flame Ionization Detector (FID) or Mass Spectrometry (MS) was employed for detection.
Retention Time: Carisoprodol showed a specific retention time, making it detectable among other compounds.
Sensitivity: A low limit of detection (0.01 µg/mL) was achieved for Carisoprodol.
Linearity and Precision: Linear relationships between concentration and peak area, and repeatability with CV values <2%.
Additional insights
If he considers using a capillary column with a narrower diameter (e.g., 0.25 mm ID), it could improve peak sharpness and separation efficiency.
If he includes headspace GC for sample preparation, it could simplify analysis by minimizing and interference from the matrix.



CE (Capillary Electrophoresis)
Development:
Sample Preparation: Carisoprodol would be dissolved in a suitable buffer for electrophoresis.
Electrophoresis Conditions: A capillary column with a buffer solution will be used, and an electric field will separate Carisoprodol based on its charge and size.
Detector: UV absorbance is commonly used for detecting the compounds.
Electropherogram: The electropherogram will show peaks corresponding to different components, with migration time on the x-axis and signal intensity on the y-axis. The peak corresponding to Carisoprodol will show up based on its migration time.[23-25]
Key Parameters by Bhat R, et al. (2015) - Spectrofluorimetric Determination of Carisoprodol. Asian Journal of Chemistry
Electrophoresis Conditions: The separation was carried out using a capillary column with an electric field, focusing on the charge-to-size ratio of Carisoprodol.
Detector: UV absorbance detection was used to monitor Carisoprodol.
Electropherogram: Carisoprodol was separated based on its migration time.
Correlation Coefficient (r): The linearity of the method was confirmed with > 0.999 r.
LOD/LOQ: Low detection and quantification limits were achieved through method optimization.
Additional insights
If he uses micellar electrokinetic chromatography (MEKC), it can provide enhanced resolution for neutral or weakly charged analytes like Carisoprodol.
If he combines capillary electrophoresis (CE) with mass spectrometry (MS), it can offer greater sensitivity and improved identification of analytes.

FTIR (Fourier Transform Infrared Spectroscopy)
Development:
Sample Preparation: Prepare a pellet with Carisoprodol and KBr or use a neat sample. Carisoprodol can be analyzed in solid form or as a solution in an appropriate solvent.
Spectral Range: FTIR scans the sample from 4000 cm^{-1} to 400 cm^{-1}.[15]
Graph: The FTIR spectrum will show absorption peaks along the y-axis (transmittance or absorbance) and wavenumber on the x-axis (cm^{-1}). Characteristic functional groups of
Carisoprodol (e.g., C-H, N-H, C=O) will produce distinctive peaks in the spectrum.[15]
Identification: By comparing the spectrum to known reference spectra, you can confirm the presence of Carisoprodol or its derivatives.[15]
Key Parameters by Sharma M, et al. (2012) - UV-Spectrophotometric Analysis of Carisoprodol in Formulations. Indian Journal of Pharmaceutical Sciences
Sample Preparation: A KBr pellet was prepared with Carisoprodol for solid-state analysis.
Spectral Range: FTIR was used to scan over a range of 4000 cm^{-1} to 400 cm^{-1}.
Characteristic Peaks: Key functional groups, such as C-H, N-H, and C=O bonds, were observed, providing a distinct fingerprint for Carisoprodol.
Sensitivity: The LOD was determined based on the intensity of the characteristic peaks.
Precision and Specificity: Reproducibility was confirmed with spectra consistent across samples.



Additional insights
If he uses chemometric techniques, such as principal component analysis (PCA), to analyze FTIR data, it can help

detect minor compositional changes.
If he extends the analysis to study excipient interactions, it can identify potential spectral interference

General Steps in Method Development
Understand Drug Properties
Study Carisoprodol's solubility, pKa, UV absorbance, and chemical stability.[24]

Select Analytical Technique
Base the choice on drug characteristics and the required sensitivity.[5]

Optimize Conditions
Adjust parameters like solvent, wavelength, mobile phase, or temperature to improve separation or detection.[24]

Validation
Follow ICH guidelines (Q2R1) to validate the method for accuracy, precision, specificity, robustness, LOD,[5]

S.No.	Methods	Description	Reference
1	UV-SPECTROSCOPY	λ Max(nm):225(nm) Correlation coefficient(r);0.9995 Precision:< 2 LOD(µg/ml) :0.10 LOQ(µg/ml):0.30 Standard error:0.002	[2,15,18]
2	HPLC	λ max(nm): 214 nm Correlation coefficient (r):0.9998 LOD(µg/ml) :0.05 LOQ(µg/ml):0.15 Standard error:0.005	[19,20,26]
3	TLC	Lenearity(ng/ml): Retention factor (RF):0.46-0.50 Accuracy (% recovery): 98-102	[21,22,27]
4	GC	Retention time (RT): 3.2 min Limit of Detection (LOD): 0.01 µg/mL Limit of Quantification (LOQ): 0.05 µg/mL Precision: < 1.5%	[28, 29, 30}
5	CE	5. Capillary Electrophoresis (CE): Migration time: 6min Limit of Detection (LOD): 0.02 µg/mL Limit of Quantification (LOQ): 0.06 µg/mL Correlation coefficient (r): 0.9994	{31,32,33}
6	FTIR	Wavelength : 1725 cm^{-1} Limit of Detection (LOD): 0.5 µg/mL Functional group detection: Yes Precision: < 2%	(34,35,36)

CONCLUSION

HPLC remains the gold standard for Carisoprodol analysis due to its versatility and robustness. However, techniques like UV-Spectroscopy, GC, TLC, CE, FTIR and HPLC by offering specific advantages, making them indispensable tools in pharmaceutical quality control [27][30].

REFERENCES

1. Brunton LL, et al. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 13th edition. McGraw-Hill Education.
2. Patel J, et al. Development of HPLC Method for Carisoprodol. International Journal of Pharmaceutical Sciences. Vol. 8, Issue 2, 2019.
3. FDA Label for Carisoprodol, 2023. U.S. Food and Drug Administration.
4. Indian Pharmacopoeia Commission. Analytical Methods for Bulk Drugs. 9th Edition, 2022.
5. ICH Q2(R1). Validation of Analytical Procedures: Text and Methodology. International Council for Harmonisation, 2005.
6. Clinical Pharmacokinetics of Muscle Relaxants. Springer Publishing, 2016.
7. Snyder JJ, et al. Pharmacokinetics of Carisoprodol in Humans. European Journal of Clinical Pharmacology.

Vol. 45, 1993.
8. Gauthier J, et al. Carisoprodol as a Central Muscle Relaxant. Clinical Pharmacology and Therapeutics. Vol. 82, Issue 4, 2007.
9. Lippmann S, et al. Metabolism of Carisoprodol to Meprobamate. Journal of Clinical Psychiatry. Vol. 50, 1989.
10. Tripathi KD. Essentials of Medical Pharmacology. 9th Edition. Jaypee Brothers Medical Publishers, 2023.
11. Wilson K, et al. A Comparative Study of Analytical Techniques for Carisoprodol. Journal of Chromatography A. Vol. 1217, Issue 10, 2010.
12. Singh B, et al. RP-HPLC Method for Estimation of Carisoprodol in Bulk Drug. Journal of Pharmaceutical and Biomedical Analysis. Vol. 56, 2011.
13. Mendelson G, et al. Toxicity Profile of Carisoprodol and Meprobamate. Annals of Internal Medicine. Vol. 96, Issue 3, 1982.
14. Dahlqvist R, et al. Analytical and Pharmacokinetic Studies on Carisoprodol. Acta Pharmacologica et Toxicologica. Vol. 61, 1987.
15. Sharma M, et al. UV-Spectrophotometric Analysis of Carisoprodol in Formulations. Indian Journal of Pharmaceutical Sciences. Vol. 74, Issue 1, 2012.
16. Beasley CM, et al. Sedative and Muscle Relaxant Effects of Carisoprodol. CNS Drugs. Vol. 24, Issue 2, 2010.
17. Wang J, et al. Gas Chromatographic Analysis of Carisoprodol. Journal of Analytical Toxicology. Vol. 33, Issue 5, 2009.
18. Martin R, et al. A Study on the Efficacy of Carisoprodol in Pain Management. Pain Practice. Vol. 12, Issue 4, 2012.
19. Goyal RK, et al. Chromatographic Methods for Muscle Relaxants. Journal of Pharmaceutical Analysis. Vol. 3, Issue 3, 2013.
20. James R, et al. Detection of Carisoprodol and Meprobamate in Biological Fluids. Journal of Forensic Sciences. Vol. 58, Issue 4, 2013.
21. Dixit K, et al. TLC as a Qualitative Tool for Carisoprodol Analysis. International Journal of Pharmaceutical Research. Vol. 5, Issue 2, 2015.
22. European Pharmacopoeia. Guidelines for Analytical Method Development. 11th Edition, 2023.
23. Bhat R, et al. Spectrofluorimetric Determination of Carisoprodol. Asian Journal of Chemistry. Vol. 27, Issue 6, 2015.
24. United States Pharmacopeia (USP). Carisoprodol Monograph. 2023 Edition.
25. Seth SD. Textbook of Pharmacology. 4th Edition, Elsevier India, 2020.
26. Gupta P, et al. Analytical Advances in Pharmaceutical Drug Estimation. Critical Reviews in Analytical Chemistry. Vol. 50, Issue 1, 2020.
27. Kapoor S, et al. Sensitivity and Specificity of HPLC for Muscle Relaxants. Journal of Pharmaceutical and Biomedical Research. Vol. 7, Issue 3, 2018.
28. Basu S, et al. LC-MS for the Simultaneous Estimation of Carisoprodol and Meprobamate. Bioanalysis. Vol. 12, Issue 2, 2020.
29. Diaz S, et al. Accuracy and Precision Studies on Carisoprodol Formulations. Drug Development and Industrial Pharmacy. Vol. 44, Issue 6, 2018.
30. Mandal A, et al. Optimization of Analytical Parameters for Carisoprodol Detection. Journal of Chromatographic Science. Vol. 58, Issue 3, 2020.